Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

PET/CT versus standard imaging for prediction of survival in patients with recurrent head and neck squamous cell carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Does Estimated Pulse Wave Velocity Add Prognostic Information? MORGAM Prospective Cohort Project

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exploration of pathophysiological pathways for incident atrial fibrillation using a multiplex proteomic chip

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Max Rohde
  • Anne L Nielsen
  • Manan Pareek
  • Jørgen Johansen
  • Jens A Sørensen
  • Anabel Diaz
  • Mie K Nielsen
  • Janus Mølgaard Christiansen
  • Jon T Asmussen
  • Nina Nguyen
  • Oke Gerke
  • Anders Thomassen
  • Abass Alavi
  • Poul Flemming Høilund-Carlsen
  • Christian Godballe
Vis graf over relationer

The purpose of this study was to examine whether staging with 18F-FDG PET/CT better predicts survival in patients with recurrent head and neck squamous cell carcinoma (HNSCC) than chest x-ray (CXR) plus head and neck MRI or chest CT (CCT) plus head and neck MRI. Methods: This was a prospective cohort study based on paired data. Consecutive patients with histologically verified HNSCC recurrence were enrolled from September 2013 to March 2016. All patients underwent CXR/MRI, CCT/MRI, and PET/CT on the same day and before biopsy. All imaging studies underwent masked interpretation by separate teams of experienced nuclear physicians or radiologists. Recurrent carcinomas were categorized as localized (equivalent to primary stages I–II), locally advanced (equivalent to primary stages III–IVB), or metastatic (equivalent to primary stage IVC). Discriminative abilities for each imaging strategy with respect to cancer-specific and stage-based survival were compared using Kaplan–Meier analysis, Cox proportional-hazards regression with the Harrell concordance index (C-index), and net reclassification improvement. Results: In total, 110 patients (90 men and 20 women; median age, 66 y; range, 40–87 y) were included. PET/CT significantly changed the assigned tumor stage when compared with imaging strategies based on CXR/MRI or CCT/MRI (P, 0.001 for both). Kaplan–Meier analysis of PET/CT-based staging showed progressively worsened prognosis with localized, locally advanced, or metastatic disease (log-rank test, P, 0.001), whereas CXR/MRI and CCT/MRI were unable to distinguish between these groups in terms of survival (log-rank test, P 5 0.18 and P 5 0.58, respectively). Overall discriminative ability in predicting cancer-specific mortality was significantly greater for PET/CT (C-index, 0.72) than for CXR/MRI (C-index, 0.55) (P 5 0.001) and CCT/MRI (C-index, 0.55)(P, 0.001). The addition of PET/CT to either CXR/MRI or CCT/MRI was associated with a significantly positive net reclassification improvement (P, 0.001 for both). Conclusion: Contrary to standard imaging strategies, PET/CT-based staging in recurrent HNSCC was able to significantly discriminate among the survival courses of patients with local, locally advanced, or metastatic disease and predict their respective survival probability.

OriginalsprogEngelsk
TidsskriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Vol/bind60
Udgave nummer5
Sider (fra-til)592-599
Antal sider8
ISSN0161-5505
DOI
StatusUdgivet - 2019

ID: 56444710